These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 27240457)

  • 21. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
    O'Malley BW; Li D; McQuone SJ; Ralston R
    Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TLR activation pathways in HIV-1-exposed seronegative individuals.
    Biasin M; Piacentini L; Lo Caputo S; Naddeo V; Pierotti P; Borelli M; Trabattoni D; Mazzotta F; Shearer GM; Clerici M
    J Immunol; 2010 Mar; 184(5):2710-7. PubMed ID: 20124101
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dendritic cells and cytokines in immune rejection of cancer.
    Ferrantini M; Capone I; Belardelli F
    Cytokine Growth Factor Rev; 2008 Feb; 19(1):93-107. PubMed ID: 18054517
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oncolytic Immunotherapy for Treatment of Cancer.
    Tsun A; Miao XN; Wang CM; Yu DC
    Adv Exp Med Biol; 2016; 909():241-83. PubMed ID: 27240460
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibody Therapies in Cancer.
    Wang S; Jia M
    Adv Exp Med Biol; 2016; 909():1-67. PubMed ID: 27240456
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radiation therapy and Toll-like receptor signaling: implications for the treatment of cancer.
    Roses RE; Xu M; Koski GK; Czerniecki BJ
    Oncogene; 2008 Jan; 27(2):200-7. PubMed ID: 18176601
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis].
    Herskind C; Fleckenstein K; Lohr J; Li CY; Wenz F; Lohr F
    Strahlenther Onkol; 2004 Apr; 180(4):187-93. PubMed ID: 15057428
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours.
    Conroy H; Marshall NA; Mills KH
    Oncogene; 2008 Jan; 27(2):168-80. PubMed ID: 18176598
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Toll-like receptor-agonists in the treatment of skin cancer: history, current developments and future prospects.
    Wenzel J; Tormo D; Tüting T
    Handb Exp Pharmacol; 2008; (183):201-20. PubMed ID: 18071661
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TLR agonists: our best frenemy in cancer immunotherapy.
    Kaczanowska S; Joseph AM; Davila E
    J Leukoc Biol; 2013 Jun; 93(6):847-63. PubMed ID: 23475577
    [TBL] [Abstract][Full Text] [Related]  

  • 31. siRNA and cancer immunotherapy.
    Ghafouri-Fard S; Ghafouri-Fard S
    Immunotherapy; 2012 Sep; 4(9):907-17. PubMed ID: 23046235
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Noncoding RNAs: the shot callers in tumor immune escape.
    Liu L; Wang Q; Qiu Z; Kang Y; Liu J; Ning S; Yin Y; Pang D; Xu S
    Signal Transduct Target Ther; 2020 Jun; 5(1):102. PubMed ID: 32561709
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cancers take their Toll--the function and regulation of Toll-like receptors in cancer cells.
    Chen R; Alvero AB; Silasi DA; Steffensen KD; Mor G
    Oncogene; 2008 Jan; 27(2):225-33. PubMed ID: 18176604
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Toll-like receptor signaling in anti-cancer immunity.
    Okamoto M; Sato M
    J Med Invest; 2003 Feb; 50(1-2):9-24. PubMed ID: 12630564
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quantitative expression of Toll-like receptor-2, -4, and -9 in dendritic cells generated from blasts of patients with acute myeloid leukemia.
    Schmitt A; Li L; Giannopoulos K; Greiner J; Reinhardt P; Wiesneth M; Schmitt M
    Transfusion; 2008 May; 48(5):861-70. PubMed ID: 18208411
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Unique features of chicken Toll-like receptors.
    Keestra AM; de Zoete MR; Bouwman LI; Vaezirad MM; van Putten JP
    Dev Comp Immunol; 2013 Nov; 41(3):316-23. PubMed ID: 23628643
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination strategies for enhancing the efficacy of immunotherapy in cancer patients.
    Moschella F; Proietti E; Capone I; Belardelli F
    Ann N Y Acad Sci; 2010 Apr; 1194():169-78. PubMed ID: 20536466
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunomodulators for skin cancer.
    Villa AM; Berman B
    J Drugs Dermatol; 2004; 3(5):533-9. PubMed ID: 15552605
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Murine IL-2 secreting recombinant Bacillus Calmette-Guerin augments macrophage-mediated cytotoxicity against murine bladder cancer MBT-2.
    Yamada H; Matsumoto S; Matsumoto T; Yamada T; Yamashita U
    J Urol; 2000 Aug; 164(2):526-31. PubMed ID: 10893638
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Toll-like receptors and immune regulation: implications for cancer therapy.
    Wang RF; Miyahara Y; Wang HY
    Oncogene; 2008 Jan; 27(2):181-9. PubMed ID: 18176599
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.